Janney Montgomery Scott LLC Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Janney Montgomery Scott LLC lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,395 shares of the company’s stock after selling 413 shares during the period. Janney Montgomery Scott LLC’s holdings in Neurocrine Biosciences were worth $1,889,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in NBIX. ProShare Advisors LLC grew its position in Neurocrine Biosciences by 3.3% during the first quarter. ProShare Advisors LLC now owns 11,829 shares of the company’s stock valued at $1,631,000 after acquiring an additional 383 shares during the period. State Board of Administration of Florida Retirement System grew its position in Neurocrine Biosciences by 2.0% during the first quarter. State Board of Administration of Florida Retirement System now owns 109,446 shares of the company’s stock valued at $15,095,000 after acquiring an additional 2,153 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Neurocrine Biosciences by 34.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,194 shares of the company’s stock valued at $7,612,000 after acquiring an additional 14,015 shares during the period. Blair William & Co. IL grew its position in Neurocrine Biosciences by 5.9% during the first quarter. Blair William & Co. IL now owns 8,599 shares of the company’s stock valued at $1,186,000 after acquiring an additional 481 shares during the period. Finally, RFP Financial Group LLC grew its position in Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after acquiring an additional 149 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 1.2 %

NBIX stock opened at $125.51 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $107.84 and a twelve month high of $157.98. The company has a market cap of $12.71 billion, a PE ratio of 33.65 and a beta of 0.35. The business’s 50-day simple moving average is $118.47 and its 200 day simple moving average is $132.93.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of recent research reports. Raymond James restated an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Robert W. Baird boosted their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Royal Bank of Canada reduced their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Barclays reduced their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Finally, Oppenheimer boosted their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.